The American Society for Bone and Mineral Research developed 13 clinical recommendations (7 primary and 6 secondary) to address the undertreatment of osteoporosis-related fractures and prevent secondary fracture among persons aged ≥65 years with hip or vertebral fractures.
The diagnosis of osteoporosis was overrepresented in patients receiving high-dose and underrepresented in patients receiving low-dose statin treatment.
The Company is currently conducting a comparative study with the aim of having the treatment designated as a therapeutic equivalent to Forteo.
A meta-analysis found that teriparatide and denosumab may be the most efficacious therapy for prevention of glucocorticoid-induced vertebral fractures.
High GLP-1 levels were associated with reduced risk for osteoporosis in postmenopausal women.
The study, presented at the American Society for Bone and Mineral Research 2019 Annual Meeting, described the experience of patients who initiated treatment with abaloparatide.
Researchers assessed the effect of genetically predicted higher serum calcium levels on bone mineral density and the risk for fracture, using Mendelian randomization.
For postmenopausal women with osteoporosis, combined treatment with teriparatide 40 μg and denosumab can increase spine and hip bone mineral density more significantly than standard combination therapy.
Follicle-stimulating hormone levels may independently predict ongoing or imminent bone loss during the menopausal transition.
A retrospective study was performed to investigate the effects of TNFi on bone mineral density in patients with RA who received bisphosphonate.
Exposure to lead is associated with decreased bone mineral density at the femur and spine and increased risk for fracture.
During the initial management of acute osteoporotic spinal fracture, different types of anti-osteoporosis medication may result in different clinical and radiologic outcomes.
Want to read more?
Please login or register first to view this content.
Next post in Bone Metabolism